Idexx Laboratories, Inc. (IDXX)

$436.98

+0.12

(+0.03%)▲

Market is closed - opens 7 PM, 29 Sep 2023

Insights on Idexx Laboratories, Inc.

  • Increasing Revenue

    Revenue is up for the last 3 quarters, 828.56M → 943.63M (in $), with an average increase of 6.3% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 3 quarters, 172.20M → 224.23M (in $), with an average increase of 12.1% per quarter

Performance

  • $434.98
    $441.37
    $436.98
    downward going graph

    0.46%

    Downside

    Day's Volatility :1.45%

    Upside

    0.99%

    downward going graph
  • $317.06
    $564.74
    $436.98
    downward going graph

    27.44%

    Downside

    52 Weeks Volatility :43.86%

    Upside

    22.62%

    downward going graph

Returns

PeriodIdexx Laboratories, Inc.Sector (Health Care)Index (NASDAQ Composite)
3 Months
-11.63%
-1.7%
-3.7%
6 Months
-10.39%
1.3%
9.8%
1 Year
31.66%
5.1%
21.9%
3 Years
13.07%
24.3%
18.1%

Highlights

Market Capitalization
35.9B
Book Value
$13.17
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
9.34
PE Ratio
46.3
PEG Ratio
7.21
Wall Street Target Price
579.13
Profit Margin
22.52%
Operating Margin TTM
29.82%
Return On Assets TTM
23.91%
Return On Equity TTM
102.06%
Revenue TTM
3.5B
Revenue Per Share TTM
42.31
Quarterly Revenue Growth YOY
9.700000000000001%
Gross Profit TTM
2.0B
EBITDA
1.2B
Diluted Eps TTM
9.34
Quarterly Earnings Growth YOY
0.71
EPS Estimate Current Year
9.84
EPS Estimate Next Year
11.15
EPS Estimate Current Quarter
2.47
EPS Estimate Next Quarter
2.4

Analyst Recommendation

Buy
    72%Buy
    27%Hold
    0
    0%Sell
Based on 18 Wall street analysts offering stock ratings for Idexx Laboratories, Inc.(by analysts ranked 0 to 5 stars)
Based on 18 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
13
13
12
Hold
5
5
7
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 32.53%

Current $436.98
Target $579.13

Company Financials

FY17Y/Y Change
Revenue
2.0B
↑ 10.91%
Net Income
263.1M
↑ 18.51%
Net Profit Margin
13.36%
↑ 0.85%
FY18Y/Y Change
Revenue
2.2B
↑ 12.4%
Net Income
377.0M
↑ 43.28%
Net Profit Margin
17.04%
↑ 3.68%
FY19Y/Y Change
Revenue
2.4B
↑ 8.75%
Net Income
427.7M
↑ 13.44%
Net Profit Margin
17.77%
↑ 0.73%
FY20Y/Y Change
Revenue
2.7B
↑ 12.45%
Net Income
581.8M
↑ 36.02%
Net Profit Margin
21.49%
↑ 3.72%
FY21Y/Y Change
Revenue
3.2B
↑ 18.79%
Net Income
744.8M
↑ 28.03%
Net Profit Margin
23.17%
↑ 1.68%
FY22Y/Y Change
Revenue
3.4B
↑ 4.73%
Net Income
679.1M
↓ 8.83%
Net Profit Margin
20.17%
↓ 3.0%
Q1 FY22Q/Q Change
Revenue
836.5M
↑ 4.43%
Net Income
194.0M
↑ 19.16%
Net Profit Margin
23.19%
↑ 2.87%
Q2 FY22Q/Q Change
Revenue
860.5M
↑ 2.87%
Net Income
132.0M
↓ 31.96%
Net Profit Margin
15.34%
↓ 7.85%
Q3 FY22Q/Q Change
Revenue
841.7M
↓ 2.19%
Net Income
180.9M
↑ 37.1%
Net Profit Margin
21.5%
↑ 6.16%
Q4 FY22Q/Q Change
Revenue
828.6M
↓ 1.56%
Net Income
172.2M
↓ 4.83%
Net Profit Margin
20.78%
↓ 0.72%
Q1 FY23Q/Q Change
Revenue
900.2M
↑ 8.64%
Net Income
214.1M
↑ 24.3%
Net Profit Margin
23.78%
↑ 3.0%
Q2 FY23Q/Q Change
Revenue
943.6M
↑ 4.83%
Net Income
224.2M
↑ 4.76%
Net Profit Margin
23.76%
↓ 0.02%
FY17Y/Y Change
Total Assets
1.7B
↑ 11.94%
Total Liabilities
1.8B
↑ 7.83%
FY18Y/Y Change
Total Assets
1.5B
↓ 10.28%
Total Liabilities
1.5B
↓ 12.49%
FY19Y/Y Change
Total Assets
1.8B
↑ 19.2%
Total Liabilities
1.7B
↑ 6.99%
FY20Y/Y Change
Total Assets
2.3B
↑ 25.22%
Total Liabilities
1.7B
↑ 0.43%
FY21Y/Y Change
Total Assets
2.4B
↑ 6.22%
Total Liabilities
1.7B
↑ 5.14%
FY22Y/Y Change
Total Assets
2.7B
↑ 12.7%
Total Liabilities
2.1B
↑ 22.37%
Q1 FY22Q/Q Change
Total Assets
2.6B
↑ 6.38%
Total Liabilities
2.0B
↑ 11.77%
Q2 FY22Q/Q Change
Total Assets
2.6B
↑ 0.56%
Total Liabilities
2.2B
↑ 10.1%
Q3 FY22Q/Q Change
Total Assets
2.6B
↑ 1.26%
Total Liabilities
2.2B
↑ 0.65%
Q4 FY22Q/Q Change
Total Assets
2.7B
↑ 4.04%
Total Liabilities
2.1B
↓ 1.2%
Q1 FY23Q/Q Change
Total Assets
1.7B
↓ 39.6%
Total Liabilities
2.0B
↓ 7.99%
Q2 FY23Q/Q Change
Total Assets
1.7B
↑ 1.98%
Total Liabilities
1.8B
↓ 9.68%
FY17Y/Y Change
Operating Cash Flow
373.3M
↑ 11.57%
Investing Cash Flow
-138.7M
↑ 52.76%
Financing Cash Flow
-208.0M
↓ 4.5%
FY18Y/Y Change
Operating Cash Flow
400.1M
↑ 7.18%
Investing Cash Flow
138.6M
↓ 199.94%
Financing Cash Flow
-597.8M
↑ 187.38%
FY19Y/Y Change
Operating Cash Flow
459.2M
↑ 14.77%
Investing Cash Flow
-205.5M
↓ 248.29%
Financing Cash Flow
-286.4M
↓ 52.09%
FY20Y/Y Change
Operating Cash Flow
648.1M
↑ 41.14%
Investing Cash Flow
-109.4M
↓ 46.78%
Financing Cash Flow
-248.4M
↓ 13.27%
FY21Y/Y Change
Operating Cash Flow
755.5M
↑ 16.59%
Investing Cash Flow
-293.0M
↑ 167.85%
Financing Cash Flow
-697.4M
↑ 180.74%
Q1 FY22Q/Q Change
Operating Cash Flow
114.7M
↓ 45.37%
Investing Cash Flow
-41.8M
↓ 5.0%
Financing Cash Flow
-13.5M
↓ 91.87%
Q2 FY22Q/Q Change
Operating Cash Flow
65.9M
↓ 42.59%
Investing Cash Flow
-55.1M
↑ 31.66%
Financing Cash Flow
-91.9M
↑ 581.8%
Q3 FY22Q/Q Change
Operating Cash Flow
189.0M
↑ 187.02%
Investing Cash Flow
-49.2M
↓ 10.69%
Financing Cash Flow
-148.8M
↑ 61.93%
Q1 FY23Q/Q Change
Operating Cash Flow
183.9M
↑ 6.05%
Investing Cash Flow
-39.5M
-
Financing Cash Flow
-146.1M
↑ 25.16%
Q2 FY23Q/Q Change
Operating Cash Flow
200.3M
↑ 8.92%
Investing Cash Flow
-27.5M
↓ 30.48%
Financing Cash Flow
-151.0M
↑ 3.39%

Technicals Summary

Sell

Neutral

Buy

Idexx Laboratories, Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
-14.57%
-10.39%
31.66%
13.07%
75.5%
Agilent Technologies Inc.
Agilent Technologies Inc.
-7.86%
-16.69%
-9.97%
10.26%
55.07%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
-9.43%
-9.39%
-3.77%
16.32%
104.15%
Danaher Corp.
Danaher Corp.
-6.37%
-0.12%
-7.06%
17.95%
127.72%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
-12.19%
2.48%
11.34%
30.64%
55.46%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
46.3
46.3
7.21
9.84
1.02
0.24
0.0
13.17
Agilent Technologies Inc.
Agilent Technologies Inc.
28.99
28.99
2.36
5.42
0.21
0.09
0.01
18.99
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
34.01
34.01
4.28
22.38
0.13
0.05
0.0
113.36
Danaher Corp.
Danaher Corp.
29.01
29.01
3.24
8.83
0.13
0.06
0.0
70.06
Iqvia Holdings Inc.
Iqvia Holdings Inc.
34.12
34.12
1.48
10.31
0.2
0.05
0.0
31.39
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
Buy
$35.9B
75.5%
46.3
22.52%
Agilent Technologies Inc.
Agilent Technologies Inc.
Buy
$32.4B
55.07%
28.99
16.2%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
Buy
$192.3B
104.15%
34.01
13.14%
Danaher Corp.
Danaher Corp.
Buy
$182.7B
127.72%
29.01
20.95%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
Buy
$36.8B
55.46%
34.12
7.47%

Institutional Holdings

  • BlackRock Inc

    10.42%

  • Vanguard Group Inc

    9.93%

  • State Street Corporation

    4.54%

  • AllianceBernstein L.P.

    4.33%

  • Fundsmith LLP

    3.57%

  • BAMCO Inc

    2.86%

Company Information

idexx laboratories, inc. (nasdaq: idxx) is a leader in pet healthcare innovation, serving practicing veterinarians around the world with a broad range of diagnostic and information technology-based products and services. headquartered in southern maine, idexx conducts operations through more than 70 locations around the world, serves customers in over 175 countries, and employs more than 6,000 people. idexx's primary business focuses on pet health, a growing market around the world. idexx products —in-clinic diagnostic tests and instrumentation, reference laboratory and telemedicine consultation services, and practice management software—enhance the ability of veterinarians to provide advanced medical care, improve staff efficiency and to build more economically successful practices. idexx also develops and manufactures diagnostic tests and information for the global production animal industry, including poultry and livestock, as well as tests for the quality and safety of water an

Organization
Idexx Laboratories, Inc.
Employees
11000
CEO
Mr. Jonathan J. Mazelsky
Industry
Health Technology

Discover More

FAQs